Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate Cancer.

HOST-response adjuvant therapy progression-free survival prostate cancer radical prostatectomy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 May 2024
Historique:
received: 11 04 2024
revised: 06 05 2024
accepted: 13 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

Given the variable clinical course of prostate cancer and the limitations of current prognostic factors, this study was conducted to investigate the impact of a histologically overt stromal response (HOST-response) to prostate cancer on clinical outcomes after radical prostatectomy. This retrospective analysis utilized The Cancer Genome Atlas (TCGA) to evaluate data from individuals with a confirmed diagnosis of prostate cancer who underwent radical prostatectomy and had available pathology slides. These slides were assessed for the presence of a HOST-response, similar to desmoplasia. The primary endpoint was progression-free survival (PFS). A multivariable competing risk regression analysis was used to assess whether a significant association existed between HOST-response and PFS, adjusting for known prostate cancer prognostic factors. Among the 348 patients analyzed, 166 (47.70%) demonstrated a HOST-response. After a median follow-up of 37.87 months (IQR: 21.20, 65.50), the presence of a HOST-response was significantly associated with a shorter PFS (SDHR, 2.10; 95% CI, 1.26 to 3.50; HOST-response in prostate cancer patients treated with radical prostatectomy is significantly associated with reduced PFS, suggesting a potential benefit from adjuvant therapy and highlighting the need for further investigation in a prospective randomized clinical trial.

Identifiants

pubmed: 38791950
pii: cancers16101871
doi: 10.3390/cancers16101871
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Mutlay Sayan (M)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Yetkin Tuac (Y)

Department of Statistics, Ankara University, 06100 Ankara, Türkiye.

Samet Kucukcolak (S)

Department of Pathology and Laboratory Medicine, Rutgers University, New Brunswick, NJ 07102, USA.

Mary D Rowan (MD)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Grace K Pratt (GK)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Cagdas Aktan (C)

Department of Medical Biology, Faculty of Medicine, Bandirma Onyedi Eylul University, 10250 Balikesir, Türkiye.

Elza Tjio (E)

Histopathology Department, Harrogate District Hospital, Harrogate HG2 7SX, UK.

Dilara Akbulut (D)

Laboratory of Pathology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.

Shalini Moningi (S)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Jonathan E Leeman (JE)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Peter F Orio (PF)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Paul L Nguyen (PL)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Anthony V D'Amico (AV)

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Mahmut Akgul (M)

Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, USA.

Classifications MeSH